Skip to Content

Transgenomic, Inc. (NASDAQ: TBIO)

Merger

Overview
  • Date:
  • 2/23/2017
  • Company Name:
  • Transgenomic, Inc.
  • Stock Symbol:
  • TBIO
  • Company Name - Buyer:
  • Precipio Diagnostics, LLC
  • Class Period:
  • FROM 2/17/2017
  • Status:
  • Closed/Complete
  • Merger Announcement Date:
  • 10/12/2016
  • Court:
  • U.S. District Court: Nebraska

Case Finder

Locate any case using the tools below.

NEW YORK, February 23, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Nebraska on behalf of all persons or entities who held Transgenomic, Inc. (NASDAQ: TBIO) securities on February 17, 2017 (the “Class Period”).

On October 12, 2016, the two parties announced the signing of a definitive merger agreement pursuant to which Precipio Diagnostics, LLC will acquire Transgenomic in a deal. The amount Transgenomic shareholders are anticipated to receive for their shares has not been disclosed by either company.

The complaint alleges that the company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the company.

If you held Transgenomic securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: